Palvella Director Acquires $300,000 in Stock Amid Company Offering
A Palvella Therapeutics director purchased $300,000 worth of company stock in connection with a recently closed underwritten offering. The transaction, disclosed on a Form 4, coincides with a large public share sale that generated $230 million in gross proceeds and an analyst upgrade following positive phase 3 data for the company’s QTORIN Rapamyci…